Acknowledgment: We thank GlaxoSmithKline, Brentford, Middlesex, United Kingdom, for providing medications and pill placebos for the trial. We also thank the following colleagues for contributing to this research (the specific contributions of some authors are also noted). Drs Hollon and DeRubeis were the principal investigators and oversaw the implementation of CT at the respective sites. Drs Shelton and Amsterdam were the coprincipal investigators and supervised the implementation of medication treatment. Edward Schweizer, MD, provided consultation about study design and implementation, especially early in the trial. Ms Lovett and Dr Young served as the study coordinators. Drs Salomon and O’Reardon and the late Martin Szuba, MD, served as study pharmacotherapists (along with Drs Shelton and Amsterdam). Cory P. Newman, PhD, Karl N. Jannasch, PhD, Frances Shusman, PhD, and Sandra Seidel, MSN, served as the cognitive therapists (along with Drs Hollon and DeRubeis). Jan Fawcett, MD, provided consultation on the implementation of clinical management pharmacotherapy. Aaron T. Beck, MD, Judith Beck, PhD, Christine Johnson, PhD, and Leslie Sokol, PhD, provided consultation on the implementation of CT. Madeline M. Gladis, PhD, and Dr Haman oversaw the training of the clinical interviewers, and David Appelbaum, PsyD, Laurel L. Brown, PhD, Richard C. Carson, PhD, Barrie Franklin, PhD, Nana A. Landenberger, PhD, Jessica Londa-Jacobs, PhD, Julie L. Pickholtz, PhD, Pamela Fawcett-Pressman, MEd, Sabine Schmid, MA, Ellen D. Stoddard, PhD, Michael Suminski, PhD, and Dorothy Tucker, PhD, served as project interviewers. Dr Gallop and Andrew J. Tomarken, PhD, provided statistical consultation. Joyce Bell, BA, Mr Freeman, Cara C. Grugan, BA, Nathaniel R. Herr, BA, Mary Hooper, BA, Miriam Hundert, Veni Linos, MSc, and Tynya Patton, MA, provided research support. Kelly Bemis Vitousek, PhD, provided helpful comments on an earlier draft of the manuscript.